

Arsen Osipov, MD  
CURRICULUM VITAE



---

Arsen Osipov, MD

08/01/21

---

Date

### **PROFESSIONAL CONTACT INFORMATION**

Assistant Professor, GI Medical Oncologist  
Cedars-Sinai Medical Center  
Department of Medicine, Division of Medical Oncology  
8700 Beverly Blvd, North Tower LL, AC1044  
Los Angeles, CA 90048  
Arsen.Osipov@cshs.org

### **EDUCATION**

2004-2008 Bachelor of Science (B.S.), Biochemistry and Cell Biology  
Bachelor of Arts (B.A.), History: War, Revolution and Social Change University of  
California San Diego; La Jolla, CA

2009-2013 Medical Doctorate (M.D.), Virginia Commonwealth University School of Medicine;  
Richmond, VA

2013-2016 Resident, Internal Medicine, Cedars Sinai Medical Center, Los Angeles, CA

2016-2017 Chief Resident, Internal Medicine, CSMC & Greater Los Angeles (GLA)  
Veterans Administration, Los Angeles, CA

2017-2020 Clinical and Research Fellow, Medical Oncology, Johns Hopkins University, School of  
Medicine, Baltimore, MD

2019-2020 Chief Medical Oncology Fellow, Medical Oncology, Johns Hopkins University, School  
of Medicine, Baltimore, MD

### **LICENSURE**

NPI #1598108482  
California, License #A135404  
Maryland, License #D0084244  
DEA #FO5289865  
ACLS/BLS Certification 05/2019-05/2021

### **BOARD CERTIFICATION**

10/2016 Internal Medicine, American Board of Internal Medicine (ABIM), #373607  
11/2019 Medical Oncology American Board of Internal Medicine (ABIM), #373607

## **PROFESSIONAL EXPERIENCE**

### **Present Positions:**

- 07/2020 – Present      Assistant Professor, Medical Oncologist, Division of Medical Oncology, Department of Medicine. Cedars-Sinai Cancer Center, Los Angeles, CA.
- 11/2020 – Present      Adjunct Assistant Professor, Johns Hopkins University School of Medicine, Baltimore, MD.
- 01/2021 – Present      Health Sciences Assistant Professor Step II, David Geffen School of Medicine, UCLA, Los Angeles, CA.

### **Previous Positions:**

- 2008-2009      Biotechnology Engineer, Baxter Bioscience Los Angeles, CA
- 2009      Study Director, Fractionation Facility Startup/Shutdown, Baxter Bioscience, Los Angeles, CA
- 2016-2017      Academic Hospitalist Attending, CSMC, Los Angeles, CA
- 2016-2017      Academic Hospitalist Attending, GLA West Los Angeles Veterans Hospital, Los Angeles, CA
- 2016-2017      Primary Care Attending, GLA Veterans Hospital Sepulveda Ambulatory Care Center, North Hills, CA
- 2016-2017      Attending Physician, Saban Community Clinic, Los Angeles, CA
- 2017-2019      Medical Oncology Fellow, General Medical Oncology Fellows Clinic, Oncology
- 2017-2020      Medical Oncology Fellow, Johns Hopkins University, Department of Oncology
- 2018-2020      Medical Oncology Fellow, Pancreas Multidisciplinary Clinic, Johns Hopkins Hospital
- 2019-2020      Chief Clinical and Research Medical Oncology Fellow, Johns Hopkins University, Department of Oncology

## **PROFESSIONAL ACTIVITIES:**

### **Committee Services:**

#### **CSMC:**

- 2016-2017      Committee Member, CSMC, GLA-West LA VA, Improving Medical Curriculum at WLA-VA Sepulveda Ambulatory Center, Los Angeles, CA
- 2016-2017      Leader, Journal Club, CSMC, Los Angeles, CA
- 2016-2017      Interviewer, Internal Medicine Residency Program, CSMC, Los Angeles, CA

- 2020- Interviewer, Internal Medicine Residency Program, CSMC, Los Angeles, CA
- 2020- Core Faculty Member, Cedars-Sinai Hematology/Oncology Fellowship Program, Los Angeles, CA
- 2020- Co-Leader of Pancreas Cancer Research Group
- 2021- Leader of Pancreas Cancer Multidisciplinary Clinic and Precision Medicine Program

**Other Committee Services:**

- 2017-2018 Member, JHH Immune-Related Toxicity Identification and Treatment Improvement Project, JHU, Baltimore, MD
- 2018-2020 Interviewer, Oncology Fellowship Program, John Hopkins University School of Medicine, JHU, Baltimore, MD
- 2018-2020 Co-leader, Quality Improvement project investigating Department of Oncology use of hospice informational visits and how this affects subsequent timing and utilization of hospice services, JHU, Baltimore, MD
- 2019-2020 Committee Member, Fellowship Executive Committee, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, JHU, Baltimore, MD
- 2019-2020 Co-leader, Quality Improvement Project in creating Grant Database for Oncology Fellowship, JHU, Baltimore, MD
- 2019-2020 Neoadjuvant Clinical Trials Algorithm for Pancreas Multidisciplinary Clinic, JHU, Baltimore, MD
- 2019-2020 Standardization of Pancreas Multidisciplinary Clinic and Research Database, JHU, Baltimore, MD
- 2020-2021 Alliance GI Oncology Committee Member for Pancreatic Diseases

**Quality Improvement:**

- 2020-2021 Clinical Trials Algorithm for Pancreatic Cancer Clinical Trials
- 2020-2021 Standardizing Lab Procedure in CCTO for processing of various cell types

**Professional Associations/Society Memberships:**

- 2009 Member; American Medical Association
- 2010 Member; American College of Physicians
- 2013 Member; American Society of Clinical Oncology

- 2018 Associate Member; American Association for Cancer Research
- 2018 Member; Society for Immunotherapy of Cancer
- 2019 Member; American Pancreatic Association
- 2019 Member; Pancreas Club
- 2020 Member; Cedars-Sinai Cancer
- 2020 Cedars-Sinai Clinical Scholars Program
- 2020 UCLA K Scholars Society

**Editorial Services:**

- 2019 Journal of Immunotherapy of Cancer, Reviewer
- 2019 JAMA Oncology, Invited Reviewer
- 2019 Oncotarget, Invited Reviewer
- 2020 Annals of Pancreatic Cancer, Reviewer
- 2020 American Journal of Physiology-Gastrointestinal and Liver Physiology, Invited Reviewer
- 2021 Annals of Pancreatic Cancer, Section Editor (Medical Oncology)

**Consulting Activities:**

- 2016-2017 Foundation Medicine Inc
- 2016-2017 Advisor, for Dr. Mark Noah, Governor’s Advisory Council of the American College of Physicians Southern California Region 1. Assisted in setting the direction for regional ACP activities and identifying the educational and professional needs of members. Assured that the issues that are important to local internists are represented at both a state and national congressional level.
- 2020-2021 Thirdbridge GI Cancers

**Community Services:**

- 2010 International Medical Aid to Nogorno-Karabakh, Yerevan, Armenia
- 2017-2018 Preceptor, High School Student, Baltimore MERIT Program
- 2018-2020 CUPID (Cancer in the Under-Privileged Indigent or Disadvantaged) Program Mentor, JHU, Baltimore, MD

2018-Present Telemedicine TeleOncology Project with Republic of Armenia  
2018-Present Cancer Registry for Republic of Armenia, Project with Republic of Armenia  
2020-2021 Armenia Trauma Initiative, Co-Leader

**HONORS AND SPECIAL AWARDS:**

2005-2008 UCSD Provost's Academic Honors  
2009 Baxter Bioscience Distinguished Director Award  
2009-2013 VCU School of Medicine, Dean's Merit Scholarship  
2014 Resident of the Year, 1st Year Resident Award, Saban Community Clinic at CSMC  
2015 Finalist for Rubenstein Award in Excellence for Resident Research  
2015 Leo Rigler Award for Academic Achievement "Resident of the Year 2015", CSMC  
2016 Leo Rigler Award for Academic Achievement "Resident of the Year 2016", CSMC  
2016 PHASE ONE Young Investigator Award for Cancer Translation  
2018 AACR, Accepted to Methods in Clinical Cancer Research Workshop  
2019 Conquer Cancer Foundation, Young Investigator Award, 2019 ASCO  
2019-2020 Selected for the Linda Rubin Fellow in GI Oncology Endowment  
2021 Conquer Cancer Foundation, Career Development Award, 2021 ASCO  
2021 Clinical Scholars Grant  
2021 UCLA KL2 Grant (highest score, withdrew)

**RESEARCH GRANTS AND FELLOWSHIPS RECEIVED:**

**Active/Ongoing:**

5/1/2021-3/21/2026  
K08CA259456-01 - Targeting the Stroma for Pancreatic Cancer Treatment  
Sponsor: NIH/NCI  
Total direct costs: 1,220,885  
Role: Awarded, Principal Investigator, Arsen Osipov, MD

7/2/2021-06/30/2024

2021 ASCO Conquer Cancer Career Development Award  
Manipulating the Tumor Microenvironment by FAK Inhibition to Enhance the Anti-tumor Immune Response to Anti-PD-1 Therapy  
Sponsor: ASCO-Conquer Cancer Foundation  
Total Direct Costs: \$200,000, Annual Direct Costs: 66,666  
Role: Awarded, Principal Investigator, Arsen Osipov, MD

8/1/2021-8/1/2023  
A Precision Platform for Pancreatic Cancer Response Prediction  
Sponsor: Cedars Sinai Clinical Scholars  
Total direct costs: \$30,000  
Role: Awarded, Principal Investigator, Arsen Osipov, MD

09/2020-12/2021  
CTSI Core Award Cedars-Sinai/UCLA Osipov (PI)  
Exploring the Role of Focal Adhesion Kinase in Pancreatic Cancer Role: Awarded, Principal Investigator  
Total Direct Costs: \$10,000  
Role: Principal Investigator, Arsen Osipov, MD

08/2018-08/2023  
A randomized Phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma  
Sponsor: Merck Co  
Total Direct Costs: \$1,383,287 JHU (Cedars is EIIT-PEMDEF)  
Principal Investigator: Lei Zheng, MD, PhD Role: Co-Principal Investigator, Arsen Osipov, MD

**Inactive/Completed:**

6/2014-12/2015  
A Phase I study of veliparib (ABT-888) in combination with gemcitabine and intensity modulated radiation therapy in patients with locally advanced, unresectable pancreatic cancer  
Sponsor: PHASE ONE Foundation Total Direct Costs: \$324,000  
Principal Investigator: Richard Tuli, MD, PhD Role: Co-Investigator, Arsen Osipov, MD

12/2014-11/2015  
Quantitating the Expression of PD-L1 in Resected Gastric and Gastroesophageal Adenocarcinoma  
Sponsor: Merck  
Total Direct Costs: \$75,000  
Principal Investigator: Richard Tuli, MD, PhD Role: Co-Principal Investigator, Arsen Osipov, MD

06/2015-06/2016  
Hyaluronan as a predictive and prognostic marker for pancreatic ductal adenocarcinoma & lung cancer  
Sponsor: Halozyme  
Total Direct Costs: \$188,905  
Principal Investigator: Andrew Hendifar, MD, MPH Role: Co-Investigator, Arsen Osipov, MD

01/2016-12/2016  
Quantifying glycosaminoglycan content in metastatic pancreatic cancer to liver Sponsor: Halozyme  
Total Direct Costs: \$83,459

Principal Investigator: Andrew Hendifar, MD, MPH Role: Co-Investigator, Arsen Osipov, MD

07/2018-06/2019

NIH T32

Grant #: 5T32CA009071-38

Molecular Targets for Cancer Detection and Treatment Sponsor: National Institutes of Health

Total direct costs: \$59,768

Principal Investigator: Mary Armanios Role: Awarded and Appointed

07/2019-07/2020

Dissecting the Tumor Microenvironment of Pancreatic Cancer: Mechanisms of Potentiation of Anti-PD1

Therapy by Targeting Focal Adhesion Kinase Through a Neoadjuvant Approach Sponsor: ASCO,

Conquer Cancer Foundation Young Investigator Award

Total Direct Costs: \$50,000

Role: Principal Investigator and Awarded Recipient

07/2019 - 06/2020

Linda Ruben Fellowship in Pancreatic Cancer Research

Role: Awarded and Appointed

04/2019-08/2020

Investigating the Radiosensitizing Effect of Focal Adhesion Kinase Inhibitor in Pancreatic Cancer

Sponsor: INXMed

Total Direct Costs: \$14,793 Role: Principal Investigator, Arsen Osipov, MD

## RESEARCH FOCUS AND INTERESTS:

I am interested in utilizing a neoadjuvant clinical-translational paradigm to investigate the stroma, TME and immune milieu of pancreatic ductal adenocarcinoma in order to sensitize it to immunotherapy and discover novel targets for treatment. I am also focused on developing a precision medicine based clinical translational research infrastructure for pancreatic cancer and other GI malignancies.

- |                   |  |
|-------------------|--|
| 07/2018 – Present | A Phase II Clinical Trial of GVAX Pancreas Vaccine with Cyclophosphamide in Combination with Nivolumab and Stereotactic Body Radiation Therapy [SBRT] Followed by Definitive Resection for Patients with Borderline Resectable Pancreatic Adenocarcinoma<br>Role: PI |
| 12/2017 – Present | A randomized Phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma.<br>Role: PI                               |
| 12/2020 – Present | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)<br>Role: Site-PI  |

12/2020- Present Alliance A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer  
Role: Site-PI

### **INVITED LECTURES AND PRESENTATIONS:**

June 2015 Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: Implications for adjuvant radiotherapy. UCLA Solomon Scholars 2015; Los Angeles, CA.

June 2016 Redefining the positive margin in pancreatic cancer: Impact of distance on survival. UCLA Solomon Scholars 2016; Los Angeles, CA.

May 2017 Pattern of Failure, Margin Status and Adjuvant Therapy in Pancreatic Cancer: Impact on Survival. American Radium Society Annual Meeting 2017; Colorado Springs, CO.

Nov 2020 Modulating the Tumor Microenvironment of Pancreas Cancer: The Role of Focal Adhesion Kinase, Baltimore, MD, JHU Guest Speaker

Dec 2020 Immunotherapy: A Paradigm Shift for Cancer Treatment. Medicine Grand Rounds, Cedars-Sinai

Dec 2020 Neoadjuvant Therapy in Pancreatic Cancer, CME, Torrance Memorial Medical Center, Los Angeles, CA

March 2021 Institutional Perspectives in Cancer, OncLive: GI Malignancies, From Immune Checkpoints to Vaccines: The Future of Cancer Immunotherapy, Los Angeles, CA

March 2021 Power Hour – GI oncology Conference, How I treat Advanced Pancreatic Cancer, Los Angeles, CA

April 2021 SEOUL NATIONAL UNIVERSITY HOSPITAL – CEDARS-SINAI MEDICAL CENTER International Cancer Conference, Pancreas Cancer Cedars Presenter

June 2021 Modulating the Tumor Microenvironment of Pancreas Cancer The Role and Targeting of Focal Adhesion Kinase (FAK), Los Angeles, CA

### **TEACHING ACTIVITIES**

#### **Clinical Teaching**

2016-2017 Preceptor, 3rd and 4th year Medical students, UCLA, outpatient and inpatient rotations in medicine, CSMC and VA Hospitals, Los Angeles, CA

2017 Preceptor, 4th year Medical Students, Foundation for Internship, UCLA, Taught and supervised procedures (ie lumbar puncture) for residency



2017-2018	Resident Teaching, Solid Oncology Service, JHU, Baltimore, MD
2019-2020	Oncology Fellow Case Conference Preceptor/Leader, JHU, Baltimore, MD
2020-	Residents/Fellows on Medical Oncology Consultation Service
2021-	Surgical Oncology Fellows, Outpatient Oncology Service

### **Non-Clinical Teaching**

#### Pre-doctoral Advisees/Mentees

12/13-06/17	Jason Naziri, Medical Student, Univ. of Florida [RP, 2, 3,5]
12/14-06/16	Tina Abramian, Pharmacy Student, Loma Linda
01/17-01/18	Arman Torossian, Post-baccalaureate, Tulane University
06/19-12/19	David Choi, MS-4, Morehouse SOM, JHU Cupid Program [PP8]
07/19-07/20	Shiqi Li, Summer Research Student, Tsinghua China [RP 10]
07/19-Present	Dwayne Thomas, Research Associate, JHU [PP 6]
01/20-07/20	Juliane Liberto, Graduate Student, JHU [RP 10]
08/21-Present	Omer Elmadbouh, Research Associate, CSMC
08/21-Present	John Davelaar, Research Associated, CSMC

#### Post-doctoral Advisees/Mentees

06/16-06/17	Rishi Patel, MD, Medical Resident, CSMC [AB, 6,7,9]
06/16-06/17	Jenny Zhou, MD, Medical Resident, CSMC [AB, 6,7,9]
09/20-06/21	Arjan Gower, Medicine Housestaff, CSMC [RP 14]
03/21-present	Brad Gallent, CSMC house staff PGY-3
06/16-06/18 08/20-present	Shant Thomassian, Medical Graduate, Meharry Med. College [RP 7]
08/20-07/21	Veronica R. Placencio-Hickok, Project Scientist [RP 12, PP 10,11]

### **Teaching Other:**

May 2015	Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: Implications for adjuvant radiotherapy. Rubenstein Award for Excellence in Resident Research; Los Angeles, CA
April 2017	Future of Cancer Therapy Medical Grand Rounds WLA Veterans Hospital & Sepulveda Ambulatory Care Center, Los Angeles, CA
September 2019	Modulating the Tumor Microenvironment of Pancreas Cancer: The Role of Focal Adhesion Cancer. Pancreas Cancer Precision Medicine Program, Johns Hopkins University, Baltimore, MD
December 2020	Pancreatic Cancer Medicine Housestaff Lecture
May 2021	A guide to immunotherapy toxicity management in internal medicine Medicine Housestaff Lecture
April 2021	Surgical Oncology Lecture Series. Immunotherapy: A Paradigm Shift for Cancer Treatment

## **BIBLIOGRAPHY/PUBLICATIONS:**

### **Research Papers – Peer Reviewed**

1. Lee BS, Yoon CW, **Osipov A**, Moghavem N, Nwachokor D, Amatya R, Na R, Pantoja JL, Pham MD, Black KL, Yu JS. Nanoprodugs of NSAIDs: Preparation and Characterization of Flufenamic Acid Nanoprodugs. *Journal of Drug Delivery*. 2011, Apr; 2011(980720) PMID: 21603162
2. Hendifar A, **Osipov A**, Khanuja J, Nissen NN, Naziri J, Yang W, Li Q, Tuli R. Influence of body mass index and albumin on perioperative morbidity and clinical outcomes in resected pancreatic adenocarcinoma. *PLOS ONE*. 2016, Mar; 11(3): e0152172. PMID: 27015568
3. **Osipov A**, Naziri J, Hendifar AE, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M, Annamala A, Nissen NN, Tuli R. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: Implications for adjuvant radiotherapy. *Journal of Gastrointestinal Oncology*. 2016, Apr; 7(2): 239-247. PMID: 27034792
4. Yue Y, **Osipov A**, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F- FDG PET images for Pancreatic cancer patients. *Journal of Gastrointest Oncology*. 2017 Feb;8(1):127-138 PMID: 28280617
5. **Osipov A**, Nissen N, Rutgers J, Dhall D, Naziri J, Chopra S, Li Q, Hendifar AE, Tuli R. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. *Ann Surg Oncol*. 2017 Nov;24(12):3674- 3682. PMID: 28871564.

6. David JM, Gresham G, Jabbour SK, Deek M, Thomassian S, Robertson JM, Newman NB, Herman JM, **Osipov A**, Kabolizadeh P, Tuli R. Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer. *J Gastrointest Oncol*. 2018 Aug;9(4):641-649. PMID: 30151260
7. Tuli R, Shiao SL, Nissen N, Tighiouart, M Kim S, **Osipov A**, Bryant M, Ristow L, Placencio-Hickok VR, Hoffman D, Rokhsar S, Scher K, Klempner S, Noe P, Davis MJ, Wachsmann A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar AE. A Phase I study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. *EBioMedicine*. 2019;40:375–381. PMID: 30635165
8. Yarchoan M, Huang C, Zhu Q, Ferguson A, Durham J, Anders R, Thompson E, Rozich N, Thomas D, Rodriguez C, **Osipov A**, Jesus-Acosta AD, Le D, Murphy A, Laheru A, Donehower R, Jaffee E, Zheng L, Azad N. A Phase II Study of GVAX Colon Vaccine with Cyclophosphamide and Pembrolizumab in Patients with Mismatch Repair-Proficient (MMR-p) Advanced Colorectal Cancer. *Cancer Medicine, Cancer Med*. 2020; 9: 1485– 1494. PMID: 31876399
9. **Osipov A**, Lim SJ Wang H, Popovic A, Azad, N, Laheru D, Zheng L, Jaffe E, Yarchoan M. Tumor Mutational Burden, Toxicity and Response of Immune Checkpoint Inhibitors (ICIs) Targeting PD(L)1, CTLA-4, and Combination: A Meta-Regression Analysis. [published online ahead of print, 2020 Jun 25]. *Clin Cancer Res*. 2020;clincanres.0458.2020. doi:10.1158/1078-0432.CCR-20-0458
10. **Osipov A**, Blair A, Liberto J, Wang J, Li K, Herbst B, Xu Y, Li S, Niu N, Rashid R, Ding D, Liu Y, Wang Z, Wolfgang C, Burkhart R, Laheru D, Zheng L. Inhibition of Focal Adhesion Kinase Enhances Antitumor Response of Radiation Therapy in Pancreatic Cancer Through an Immune Mechanism. *Cancer Biology and Medicine, PMCID: PMC7877172 DOI: 10.20892/j.issn.2095-3941.2020.0273*
11. Zheng L, Ding D, Edil BH, Judkin C, Durham JN, Thomas DL, Bever KM, Mo G, Solt S, Hoare J, Bhattacharya R, Zhu Q, **Osipov A**, Onners BL, Purtell K, Cai H, Parkinson RM, Hacker-Prietz A, Herman J, Le DT, Azad NS, De Jesus-Acosta A, Blair AB, Kim VM, Soares KC, Manos L, Cameron JL, Makary MA, Weiss MJ, Schulick RD, He J, Wolfgang CL, Thompson ED, Anders RA, Sugar EA, Jaffee EM, Laheru DA. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. *Clin Cancer Res*. 2020 Dec 4;clincanres.2974.2020. doi: 10.1158/1078-0432.CCR-20-2974. Epub ahead of print. PMID: 33277370.
12. Hayashi K, Nikolos F, Lee YC, Jain A, Tsouko E, Gao H, Kasabyan A, Leung HE, **Osipov A**, Jung SY, Kurtova AV, Chan KS. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. *Nat Commun*. 2020 Dec 7;11(1):6299. doi: 10.1038/s41467-020-19970-9. PMID: 33288764.
13. Anderson A, LeVee A, Kim S, Atkins K, Guan M, Placencio-Hickok V, Moshayedi N, Hendifar A, **Osipov A**, Gangi A, Burch M, Waters K, Cho M, Klempner S, Chao J, Kamrava M, Gong J. A comparison of clinicopathologic outcomes across neoadjuvant and/or adjuvant treatment modalities in resectable gastric cancer, Submitted Under Revision, JAMA Network

14. Xia T, Li K, Niu N, Shao Y, Ding D, Thomas D, Jing H, Fujiwara K, Hu H, **Osipov A**, Yuan C, Wolfgang C, Thompson; Andres R, He J, Mou Y, Murphy AG. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. Under Revision Journal of Hepatology
15. Gower A, Gresham G, Spector S, Haladjian N, Lee J, Mehta J, **Osipov A**, Hendifar A. Association of germline ATM mutations and survival in pancreatic cancer. Annals of Pancreatic Cancer, Submitted, Tentative Acceptance Pending Revision

### Chapters:

1. **Osipov A**, Tuli, R, Hendifar A, Locally Advanced Pancreatic Cancer. Hospital Physician, Hematology-Oncology Board Review Manual. Volume 12, Part 3. Turner White, Wayne. PA. 2017
2. **Osipov A**, Murphy AG, Zheng L, From Immune Checkpoints to Vaccines: The Past, Present and Future of Cancer Immunotherapy, Advances in Cancer Research: Immunotherapy of Cancer, Elsevier Science Publishing, 2019. PMID: 3120263
3. Heumann T, **Osipov A**, Murphy A Biliary Tract and Gallbladder Cancer - A Multidisciplinary Approach: Novel Biomarkers for Cholangiocarcinoma 3rd ed, submitted, In publication

### Reviews:

1. Yaffee P, **Osipov A**, Tan , Tuli R, Hendifar AE. Review of systemic therapies for locally advanced and metastatic rectal cancer. Journal of Gastrointestinal Oncology. 2015, Apr; 6(2): 185-200. PMID:25830035
2. **Osipov A**, Saung MT, Zheng L, Murphy AG. Small Molecule Immunomodulation: The Tumor Microenvironment and Overcoming Immune Escape. JITC, 2019;(7)1:224. PMID: 31439034
3. Lee PC, Hendifar A, **Osipov A**, Cho M, Li D, Gong J. Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations. Cancers (Basel). 2021 Apr 3;13(7):1706. doi: 10.3390/cancers13071706. PMID: 33916849; PMCID: PMC8038487.
4. Advances in the Treatment of Pancreatic Adenocarcinoma, Anderson, E, THomassian S, Hendifar A, **Osipov A**. Under Revision

### Editorials:

1. **Osipov A**, Zaidi N, Laheru D. Dual Checkpoint Inhibition in Pancreatic Cancer: Revealing the Limitations of Synergy and the Potential of Novel Combinations, JAMA Oncology, July 18, 2019. PMID: 31318378

### Case Reports:

1. Lin CY, Mehta P, Waters KM, **Osipov A**, Gong J. et al. Complete response to neoadjuvant pembrolizumab and capecitabine in microsatellite stable, Epstein-Barr virus-positive, locally advanced gastric adenocarcinoma: case report. *AME Case Rep.* 2021;5:30. Published 2021 Jul 25. doi:10.21037/acr-21-11

#### **Abstracts:**

1. Beas A, **Osipov A**, Farquhar MG. Downregulation of EGFR Signaling Requires Galphas. *The FASEB Journal.* 2010, Apr; 24(1): 853.2.
2. Hendifar AE, Tan CR, Yaffee P, **Osipov A**, Tuli R, Jeon CY. Evaluating outcomes of pancreatic cancer patients with cachexia. *Journal of Clinical Oncology.* 2014, Jun; 2014(32): e15208.
3. Khanuja J, Gresham G, **Osipov A**, Tuli R, Hendifar AE. Treatment and underlying mechanisms of pancreatic cancer cachexia (PANCAx study). *Journal of Clinical Oncology.* 2015, Jan; 2015(33): TPS491.
4. **Osipov A**, Naziri J, Hendifar, A, Dhall, D., Rutgers, JK, Chopra S, Li, Q, Tighiouart M, Annamalai A, Nissen NN, Tuli R. Margin clearance and lymphadenectomy in pancreatic adenocarcinoma: clinical outcomes and implications for adjuvant radiation therapy. *International Journal of Radiation Oncology Biology Physics.* 2015, Nov; 93(3): 158.
5. Tuli R, Nissen NN, Lo S, Tighiouart M, Rogatko A, **Osipov A**, Bryant M, Sandler HM, Hendifar AE. Interim analysis of a Phase I study of veliparib with gemcitabine and IMRT in patients with borderline and locally advanced unresectable pancreatic cancer. *International Journal of Radiation Oncology Biology Physics.* 2015, Nov; 93(3): E181.
6. Toll J, **Osipov A**, Khanuja J, Pan D, Patel R, Zhou J, Shinde AM, Annamalai A, Hendifar AE, Tuli R. DNA sequencing to identify potentially novel targets for therapy in pancreatic cancer. *Journal of Clinical Oncology.* 2016, Jan; 2016(34): 275.
7. Toll J, Li Q, **Osipov A**, Zhou J, Patel R, Pan D, Khanuja J, Bryant M, Tuli R, Hendifar AE. Identifying novel genetic alterations for risk stratification and prognostication in pancreatic cancer. *Journal of Clinical Oncology.* 2016, Feb; 2016(34): e15754.
8. Mathew MM, Elahi N, **Osipov A**, Bitterman A, Talcott W, Tuli R, Du KL, Thomas TO. Influence of Neutrophil-Lymphocyte Ratio and Other Independent Factors Predicting Failure in Locally Advanced Esophageal Malignancies. *International Journal of Radiation Oncology Biology Physics*, Vol. 96, Issue 2, E204, Oct, 2016
9. Larson BK, Pan D, Khanuja J, Patel R, Zhou J, **Osipov A**, Guindi M, Müller T, Li Q, Jiang P, Tuli R, Hendifar AE. Association of hyaluronan accumulation with clinical- pathologic features in pancreatic ductal adenocarcinomas. *J Clin Oncol.* 2017;35(4\_suppl):322. doi:10.1200/JCO.2017.35.4\_suppl.322
10. David J, **Osipov A**, Gresham J, Thomassian S, Hendifar, A, Tuli R. Evaluating the Role of SMAD 4 as a Predictor of Clinical Outcomes in Pancreatic Cancer, *International Journal of Radiation Oncology Biology Physics*, Volume 98, Issue 2 , E11, June 2017

11. Tuli R, Nissen N, Lo S Bryant M, **Osipov A**, Rogatko A, Tighiouart M, Liu A, Deng N, Hendifar AE, Shiao SL. DNA repair deficiency, genomic instability and immune profiling in a Phase I study of locally advanced pancreatic cancer patients treated with veliparib, gemcitabine and radiotherapy. *J Clin Oncol*. 2018;36(15\_suppl):4128. doi:10.1200/JCO.2018.36.15\_suppl.412

## Posters Presentations

1. **Osipov A**, Naziri J, Hendifar, A.E., Dhall, D., Rutgers, J.K., Chopra, S., Li, Q., Tighiouart, M., Annamalai, A., Nissen, N.N., Tuli, R Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: Implications for adjuvant radiotherapy. *J Clin Oncol* 33, 2015 (suppl 3; abstr 429) presented at ASCO GI Annual Meeting, San Francisco, CA
2. **Osipov A**, Rutgers J, Nissen N, Dhall D, Naziri J, Chopra S, Li Q, Hendifar AE, Tuli R. Redefining the Positive Margin in Pancreatic Cancer Impact of distance on Survival. *J Clin Oncol* 34, 2016 (suppl; abstr 4122). Presented at ASCO Annual Meeting 2016, Chicago, IL
3. **Osipov A**, Li Q, Thomassian S, Annamalai L, Yearley JH, Rutgers JK, Hendifar AE, Tuli R. Impact of chemoradiotherapy on PD1/PDL1 expression and clinical outcomes in gastroesophageal cancers, *J Clin Oncol* 35, 2017 (suppl; abstr 4031), Presented at ASCO Annual Meeting 2017, Chicago, IL
4. **Osipov A**, Sugar E, Ferguson A, Durham J, Rodriguez C, Parkinson R, Sena L, Zheng L, Wolfgang C, Burkhart R, Narang A, Laheru D, Azad N, Jaffee E, Weekes CD, Yarchoan M. Phase II Clinical Trial of GVAX Pancreas Vaccine (with Cyclophosphamide) in Combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients with Borderline Resectable Pancreatic. Adenocarcinoma (BR-PDAC), AACR Annual Meeting 2019, Atlanta, GA
5. **Osipov A**, Popovic A, Hopkins A, Frampton GM, Albacker A, Azad N, Laheru D, Zheng L, Jaffee EM, Yarchoan M. Tumor Mutational Burden (TMB) and Response Rates to Immune Checkpoint Inhibitors (ICIs) targeting PD-1, CTLA-4 and Combination *J Clin Oncol* 37, 2019 (suppl; abstr 2578) Presented ASCO Annual Meeting 2019, Chicago, IL
6. **Osipov A**, Li K, Choi D, Rozich N, Thomas D, Zheng L. The Implications of Focal Adhesion Kinase (FAK) on T-cell Populations in Immunotherapy Treated Pancreatic Ductal Adenocarcinoma (PDAC). American Pancreatic Association 2019, Maui, HI
7. **Osipov A**, Wang J, Li S, Choi D, Henderson M, Pachter J, Lee J Maneval D, Zheng L, Blair A, PEGylated recombinant human hyaluronidase, PEGPH20, significantly enhances the anti-tumor activity of the combination of focal adhesion kinase Inhibitor and anti-PD-1 antibody by targeting CXCR4-expressing myeloid cells in a murine model of PDAC. Poster Presentation AACR Annual Meeting 2020.
8. Placencio-Hickok R, **Osipov A**, Mehta S, Katewa SD, Zha J, Hendifar AE. Increased growth differentiation factor 15 serum levels in pancreatic cancer patients, AACR Pancreatic Cancer Conference 2021
9. **Osipov A**, Zheng L, Targeting the Stroma to Enhance T-cell Infiltration and Anti-tumor Response to Anti-PD1 Antibody in Pancreatic Ductal Adenocarcinoma. ITOC7 Annual Meeting

10. Moshayedi N, Yang J, Lagishetty V, Jacobs J, Placencio-Hickok V, **Osipov A**, Hendifar AE, Gong J. Fecal microbiome composition in pancreatic cancer cachexia and response to nutrition support. ASCO Annual 2021
11. Placencio-Hickok V, Lauzon M, Moshayedi N, Guan M, Kim S, Jacob Pandol, Larson B, Gong J, Hendifar AE, **Osipov A**. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma, primary tumors, and sites of metastasis ASCO Annual 2021